Vanderbilt Center Partners with Saravir Biopharma to Develop Novel Monoclonal Antibody Therapy for Measles

The Vanderbilt Center for Antibody Therapeutics (search)Search term has entered into a strategic option agreement with Saravir Biopharma Inc. (search)Search term to develop cutting-edge human monoclonal antibodies (search)Search drug designed to treat and prevent measles (search)Search disease infection. This collaboration addresses the escalating global challenge of measles outbreaks as vaccination rates decline and cases surge worldwide, representing a critical intervention for populations vulnerable to severe complications.

The antibodies were originally isolated through pioneering research conducted in the laboratory of Dr. James Crowe Jr., director of the Vanderbilt Center for Antibody Therapeutics (search)Search term and University Distinguished Professor of Pediatrics and Chemistry. As measles (search)Search disease cases continue to rise, this breakthrough offers a promising alternative for individuals who cannot receive traditional vaccines.

Targeting Viral Fusion Mechanisms

Preclinical investigations have demonstrated potent neutralization of measles virusView drug details particles in various animal models. According to Dr. Ronald Moss, President and CEO of Saravir Biopharma, the results are "very promising." The antibodies specifically target viral fusion proteins (search)Search target expressed on measles (search)Search disease-infected cells and free virus particles, blocking the fusion process essential for viral entry and spread.

"By impeding this critical mechanism, the antibodies effectively prevent infection at the cellular level," representing a novel approach to measles (search)Search disease management. This targeted therapy could revolutionize prophylactic and treatment strategies by neutralizing the virus extracellularly and at the infected cell surface.

Addressing Vulnerable Populations

The traditional live-virus measles (search)Search disease vaccine, while highly effective in healthy individuals, is contraindicated for at-risk groups including pregnant women and immunocompromised patients. Monoclonal antibody therapy offers immediate protection without relying on the host's immune activation, providing passive immunity by directly neutralizing the virus.

This approach is especially vital for populations disproportionately susceptible to severe complications, offering protective benefits without necessitating an active immune response. The therapy can be administered to individuals contraindicated for vaccination, filling a critical gap in current prevention strategies.

Rising Measles Threat

The United States achieved near elimination of measles (search)Search disease due to high vaccination coverage, but recent trends reveal an alarming increase in cases. The Centers for Disease Control and Prevention (CDC) reported 2,285 confirmed measles cases in 2025, with an additional 1,575 cases reported in the first quarter of 2026 alone. This resurgence is attributed largely to declining vaccine coverage and increasing vaccine hesitancy, which undermines herd immunity and facilitates viral transmission.

Measles (search)Search disease, caused by a highly contagious respiratory virus, poses significant risk to individuals who cannot mount an adequate immune response. The virus represents a critical public health challenge as outbreaks continue to threaten global health despite available vaccines.

Development Partnership

Saravir Biopharma, headquartered in Encinitas, California, was co-founded by Dr. Moss, an experienced physician-scientist with a track record of leading antiviral and vaccine development from fundamental research to advanced clinical trials. The company's mission is to develop the first monoclonal antibody-based therapeutic against measles (search)Search disease, addressing an urgent unmet clinical need.

The collaboration leverages access to human monoclonal antibodies (search)Search drug derived from natural human immune responses, providing a strong foundation for therapeutic success. Dr. Crowe's laboratory expertise in isolating and characterizing neutralizing antibodies targeting viral pathogens underpins this initiative.

Clinical Development Timeline

The next phase involves initiating human clinical trials to establish safety, dosage, and efficacy profiles. While traditional pharmaceutical development timelines are extensive, the accelerating spread of measles (search)Search disease may enable regulatory agencies to fast-track these processes, expediting access to life-saving therapies.

Dr. Moss emphasized his team's determination to advance these antibodies despite inherent challenges. "The long-predicted resurgence of measles (search)Search disease outbreaks necessitates rapid and innovative countermeasures," he stated. With extensive expertise in antiviral drug development, Saravir's leadership is positioned to translate Vanderbilt's scientific discoveries into clinically viable therapeutics.

Broader Implications

This collaboration represents a transformative approach to infectious disease therapeutics by combining cutting-edge antibody engineering with an acute public health need. The monoclonal antibodies (search)Search drug are poised to become a critical adjunct to vaccination programs, providing protection for vulnerable groups and potentially altering the landscape of measles (search)Search disease prevention and treatment.

These therapies may set a precedent for similar interventions for other viral infections, especially where traditional vaccination approaches face limitations due to immune system constraints or safety concerns. The development represents a significant milestone in the broader field of antiviral therapeutics and immunology, offering hope for reducing the incidence and severity of measles (search)Search disease worldwide.